Comprehensive genomic profiling (FoundationOne or F1)
tumor
TUMOR
Genomic alterations and TMB in 52 pre-treatment tumor tissue samples were detected using the F1 targeted next-generation sequencing panel at a CLIA-certified, CAP-accredited reference laboratory (Foundation Medicine), as previously described